Biotechnology has an increasingly significant impact on a number of life sectors and disciplines. Paramount Group of Companies founded by Lindsay Rosenwald has been working with biotechnology and life sciences for over 20 years. With a global impact on the biotechnology sector, Paramount developed, invested and supported more than 40 life sciences companies over the past 19 years, including 20 in the last 3 years. Current Portfolio Companies have over 40 product candidates that advance through clinical trials. Paramount has also a strong record on scientific, industrial, health and safety issues in biotechnology and pharmacy.
Paramount BioSciences, LLC, founded and managed by Dr. Lindsay A. Rosenwald, is focused on the in-licensing of novel therapeutic and other medical technologies and is involved in corporate companies incubation and governance as well as business development. It extensively supports infrastructure with the experience in licensing, corporate development, clinical operations, and navigation of regulatory pathways. Paramount BioCapital, Inc., a FINRA registered broker-dealer, is involved in raising capital for Paramount’s Portfolio Companies.
Paramount BioSciences Executive Leadership Team
Paramount BioSciences executive team has an extensive collective experience in biotechnology/pharmacy and financial operations.
Lindsay A. Rosenwald, M.D., Chairman and Chief Executive Officer, Founder of Paramount BioSciences. With over 20 years of experience in developing, financing, and investing in biotechnology and life science companies, Dr. Rosenwald has made a powerful contribution to the today’s biotechnology sector. He has also established a charitable foundation called The Rosenwald Foundation Inc., which deals with educational philanthropic research.
J. Jay Lobell, J.D., President and Chief Operating Officer, was a former partner at law firm Covington & Burling, where he provided business, litigation, and regulatory advice to financial institutions, corporations, and individuals.
Russell Ellison, M.D., Executive Vice President, has almost 30 years of senior management pharmaceutical experience in commercialization and drug development. His former positions as the Vice President of Clinical Development at Fibrogen, Inc. and the U.S. Vice President of Medical Affairs and Chief Medical Officer of Sanofi-Synthelabo, USA prove his ability to successfully deal with complex financial and management operations.
Advantages of Paramount BioSciences Model
What makes Paramount BioScienses the preferred acquirer of drugs and development is their flexibility on structure of collaboration and licensing. They have all the assets and skills to rapidly execute, deal and begin development work and access to the capital necessary to develop new products. With a huge clinical and commercial experience and expertise, Paramount’s mission is to maximize value to in-licensed products. Portfolio Companies can be focused on the development of a few key products by providing committed resources (human and financial) as well as a top-tier management expertise, which is focused on a specific product or field.
The structure of Portfolio Company fosters the compound’s progression through to market, eliminating possibilities of the program being shelved.
Financing Models and Related Information
In the past, Paramount Portfolio Companies were publicly traded, via initial public offering, acquisition, reverse merger, or self-registration. The following models are now employed: partnership, merger and acquisition, as well as the Private Company model.
In addition to its own investment in Portfolio Companies, Paramount Group has also raised substantial capital from outside investors. Over the past 60 months more than $400 million was raised for Paramount companies. Such companies include Ziopharm Oncology ($37MM), Cougar Biosciences ($47MM; in conjunction with SG Cowen), and Chelsea Therapeutics ($22MM).
Dr. Lindsay Rosenwald has been able to attract experienced CEO and management staff from such companies and organizations as Serono, Pfizer, Genentech, Johnson & Johnson, Roche, Biogen Idec, Sanofi Aventis, Antigenics, and Celltech. This ensures that Paramount’s commercial and financial aspects always stay on top level.
Clinical Assets of Selected Public and Private Companies Funded by Paramount BioSciences
Keryx Biopharmaceuticals: Phase II Phosphate binder; Phase II drug (Perifosine) for oncology; Phase II drug for oncology (UCN-01)
Javelin Pharmaceuticals: Phase III drug Intranasal Morphine and Intranasal Ketamine for pain relief; Pre-MAA and Phase III Injectable Diclofenac
Cougar Biotechnology: Phase III drug (Abiraterone Acetate) for prostate cancer; Phase I/II drug (Noscapine) for NHL; Phase II drug (Seocalcitol) for prostate cancer
Ziopharm Oncology: Phase II/III drug for myeloma; Phase I/II drug for sarcoma; Phase II drug for breast cancer
Hana Biosciences: Phase II/III drug for hematological malignancies; Phase I drug for EGFR inhibitor rash; Phase II anti-folate for oncology; Phase I/II camptothecin for oncology
Manhattan Pharmaceuticals: Phase II/III drug for Atopic Dermatitis; Phase III sedative buccal spray; Phase III topical head lice preparation
Chelsea Therapeutics: Phase III drug for orthostatic hypotension; Phase II drug for rheumatoid arthritis; IND stage drug for inflammatory conditions
NovaDel Pharma: Buccal spray platform technology; buccal sprays for migraine, anxiety, sleep and multiple other indications under development
Vioquest Pharmaceuticals: Phase II AKT inhibitor for solid tumors and hematological malignancies; Pre-NDA compound for Leishmaniasis; Phase II PTP inhibitor for multiple tumor types; Phase II drug for chemo-induced Hand Foot Syndrome
Tracon Pharmaceuticals, Inc.: TRC-105: Anti-CD105 monoclonal antibody addressing major cancers (prostate, breast and renal cell); TRC-93: Humanized, affinity-matured IgG and retained specificity of murine parental IgM HUI77. This antibody is active in combination with chemotherapy. TRC-102: Small molecule inhibitor of base-excision repair, shown to reverse Temodar® resistance without added toxicity
Alacrity BioSciences, Inc.: ALTY-0501: 0.025% doxycycline inhibits MMP-9 breakdown of corneal barrier. This is a novel mechanism approach to the $500 MM+ dry eye market, which currently offers limited treatment options. ALTY-0601: Small peptide therapeutic with a unique mechanism of action to reduce intraocular pressure (IOP) in patients with ocular hypertension or primary open angle glaucoma
Cutanea Life Sciences, Inc.: CLS001: Omiganan pentahydrochloride is a patented, novel peptide used to treat rosacea that has demonstrated activity against a wide variety of microorganisms, including gram-positive and gram- negative bacteria and fungi. CLS002: Next generation injectible chitosan in soft tissue augmentation. CLS003: Ionic Contra Viral Therapy in development for the treatment of cutaneous warts.
Ventrus BioSciences, Inc.: VEN309: New chemical entity for the topical treatment of hemorrhoids; mechanism of action is to inhibit venous contraction and platelet aggregation, allowing normalization of blood flow. VEN307: Diltiazem cream for anal fissures. VEN308: Phenylephrine gel for fecal incontinence.
Mt Cook Pharma, Inc.: MCP101: TRPV1-agonist; an intravesical treatment for overactive bladder (OAB) and benign prostate hyperplasia (BPH) patients who fail oral medications. MCP202: Oral, first-line delta receptor agonist treatment for OAB and BPH. MCP201: Chemically novel, injectible, mixed opioid receptor agonist for serious pain
Indigo Pharmaceuticals, Inc.: INDI-702: Synthetically derived, oral small molecule for large, chronic, cardiovascular market. Possesses both phosphodiesterase (PDE) inhibitor activity and thromboxane A2 synthetase (TxA2) inhibitor activity and demonstrated increase in peak walking time (p=0.004) compared to placebo at 24 weeks.
Coronado BioSciences, Inc.: CNDO101 (5-imino-3-deoxydoxorubicin): Rationally designed anthracycline analogue with safety advantages – Structural elements responsible for cardio-toxicity has been eliminated. CNDO102 (NK cell activator): Immunotherapy targeting minimal residual disease. The compound has already shown positive efficacy in its ongoing Phase 1 Trial. CNDO103 (Bcl-2 family protein inhibitor platform): Rationally designed, pan-Bcl-2 inhibitor with multiple oncology applications.
Related posts:
Lindsay Rosenwald – His Arm Of Charity | Lindsay Rosenwald says:
[...] of people who support Sh’or Yoshuv’s mission and dedication to Jewish learning. Dr. Lindsay Rosenwald is exemplary of these traits with his dedication to charity and community. Lindsay Rosenwald and [...]
5th April 2010 at 5:49 pm
Dr. Lindsay Rosenwald- Researches and Inventions | Lindsay Rosenwald says:
[...] is Dr. Lindsay Rosenwald who balanced the financial status of many companies with the help of Paramount BioCapital. He was a [...]
5th April 2010 at 8:08 am